Disease Landscape and Forecast Insights

Despite the wide range of treatment options available, metastatic non-small-cell lung cancer (NSCLC) remains a major cause of cancer-related death. For patients with metastatic (EGFR- and ALK-…

NSCLC is one of the most dynamic indications in oncology. In the United States, the FDAapproved six new therapies for NSCLC in 2015 and, in 2016, granted approval to Tecentriq (Roche/Genentech…

NSCLC has one of the most dynamic drug development pipelines in oncology, including multiple targeted and biomarker-driven therapies. DRG expects the NSCLC therapy market to experience robust…

Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis…

Faced with the financial pressures of reimbursing a robust pipeline of new and expensive cancer therapies, U.S. managed care organizations (MCOs) are increasing their focus on managing the…

Non-small-cell lung cancer (NSCLC) affects thousands of individuals in Brazil and Mexico, and it is managed with premium-priced targeted agents and chemotherapy. In both countries, public coverage…

Biomarker-driven prescribing in oncology is playing an increasingly important role in various diseases, from indications in which its use is well entranced such as non-small-cell lung cancer (NSCLC…

Biomarker- and histology-driven prescribing has become standard practice in the treatment of non-small-cell lung cancer (NSCLC). The treatment algorithms for NSCLC—including those for biomarker-…

Genomic aberration status, histology, performance status, and stage of disease are key factors that influence the treatment of non-small-cell lung cancer (NSCLC). The characterization of biomarker-…

Faced with the financial pressures of reimbursing a robust pipeline of new and expensive cancer therapies, U.S. managed care organizations (MCOs) are increasing their focus on managing the…

Genomic aberration status, histology, performance status, and stage of disease are key factors that influence the treatment of non-small-cell lung cancer (NSCLC). The characterization of biomarker-…

Metastatic squamous-cell NSCLC is an incurable disease associated with a dismal 5 year OS of